Navigation Links
SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
Date:3/3/2008

I-EORTC

International Conference, the Company announced the following: MP470, a

clinical-stage multi-targeted tyrosine kinase inhibitor, demonstrates

preclinical synergy with DNA damaging agents (Poster A173, Abstract

1026); S110, a decitabine-derived DNA demethylating agent, shows

improved pre-clinical activity due to increased drug delivery and

stability (Poster 140, Abstract 1038); and, the proprietary CLIMB(TM)

technology was successful in the lead development and design of small

molecule JAK2 and Pim kinase inhibitors (Posters C200, Abstract 907 and

C208, Abstract 985). Also, Dr. Peter A. Jones, Director of USC's Norris

Cancer Center, further discussed S110 in a plenary session on cancer

epigenetics.

-- The Company announced during an oral presentation at the American

Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in

Los Angeles that MP470, a clinical-stage multi-targeted tyrosine kinase

inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract

178). Activity was also demonstrated in vivo in a glioblastoma

multiforme xenograft model. Evidence presented suggests that MP470

inhibits DNA damage repair through suppression of a critical DNA repair

protein, Rad51. Dr. James Welsh of the University of Arizona, who

conducted these pre-clinical studies, also revealed that the pre-

clinical activity of MP470 against glioblastoma multiforme cells is

synergistic with radiation.

December 2007:

-- As part of a series of presentations at the American Society of

Hematology's 49th Annual Meeting, the Company described how its

proprietary CLIMB technology was used in lead development and design of

small molecule Pim kinase inhibitors (Poster 845, Abstract 2655) and

how its novel decitabine dinucleotide
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
4. Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
5. Genetic Engineering & Biotechnology News reports on advances in miRNA
6. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
7. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
8. Cepheid Reports Fourth Quarter and Full Year 2007 Results
9. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
10. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
11. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 ActiGraph, a ... solutions for the global research community, announced today that ... Board. Dr. Matsudo is the Scientific Director of the ... (CELAFISCS), a Professor of Medicine at Gama Filho University ... organized by the State Secretariat of Health of São ...
(Date:6/18/2013)... NuView Life Sciences (NLS), a privately ... diagnostic (IVD) biomarkers, today announced the results from a ... development for the early detection of Prostate and Bladder ... presentation at the 2013 Annual Meeting of the Society ... Canada on Sunday, June 9th. NLS acquired the ...
(Date:6/17/2013)... NASA deployed an improved Air ... monitor potentially harmful chemicals in the air on the ... by Draper Laboratory , is currently being used ... that is processed and re-circulated within the spacecraft or ... even in trace amounts, endangers their health. Harmful compounds ...
(Date:6/17/2013)... As a leader in the skincare industry, the team ... for acne, rosacea, and eczema. As part of Acne and ... Rosacea Society) has dedicated a month to creating awareness about ... on treatment options. Probiotic Action follows in the footsteps of ... via social networks and online resources for the acne and ...
Breaking Biology Technology:Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 2NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI 3New Monitoring System Will Better Protect NASA Astronauts on ISS 2Acne and Rosacea Awareness Month: Probiotic Action Announces their Daily News Updates with Insight on the Most Common Skin Conditions 2
... in the Materials Science and Technology division of ... injection, detection and precession of spin accumulation in ... at temperatures up to 225 degrees Celsius. These ... in Si is viable as a basis for ...
... 5, 2011 Codexis, Inc. (NASDAQ: CDXS ) ... 31, 2011.   First Quarter Financial Highlights:Revenue: ... of $31.0 million, an increase of 21% from $25.7 million ... million increased 106% over the same time period driven by ...
... 2011 In parts of the world where dengue fever ... is a waste not only of time and money. It ... infection called chikungunya—its high fever, joint pain that can last ... of dengue. Recovery from the acute phase of the infection ...
Cached Biology Technology:NRL scientists achieve high temperature milestone in silicon spintronics 2NRL scientists achieve high temperature milestone in silicon spintronics 3Codexis Reports First Quarter 2011 Results 2Codexis Reports First Quarter 2011 Results 3Codexis Reports First Quarter 2011 Results 4Codexis Reports First Quarter 2011 Results 5Codexis Reports First Quarter 2011 Results 6Codexis Reports First Quarter 2011 Results 7SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 2SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 3
(Date:6/17/2013)... Research Foundation and Horizon Pharma further establish their commitment ... 2013 AGA-Horizon Pharma Fellow Abstract Prizes and the 2013 ... year, this competition continues to grow in popularity among ... basic and clinical research," said Nicholas F. LaRusso, MD, ... extremely proud of all that these fellows and students ...
(Date:6/17/2013)... A new study ... can be reversed with treatment. The study by researchers from ... McGill University and at Universit de Montral found that blocking ... mice with advanced Alzheimer,s disease (AD) recovers memory and cerebrovascular ... in May, also suggest an underlying mechanism of AD ...
(Date:6/16/2013)... triggered a similar marine ecosystem crisis to those witnessed ... according to research published today in Nature Geoscience ... of Newcastle, UK, Cologne, Frankfurt and GEOMAR-Kiel, confirms the ... marine ecosystem during the mid-Cretaceous greenhouse period. ... and duration of the temperature change.,Analysing the geochemistry and ...
Breaking Biology News(10 mins):Horizon Pharma Abstract Prizes recognize promising fellows and students 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2Global cooling as significant as global warming 2
... a specific mutation of the COX2 gene seems to ... increasing womens susceptibility to developing the disease. The ... confirmed by further studies, it might be possible to ... ibuprofen, which are used already for other conditions, to ...
... have found evidence that supports the theory that reproductive ... at the level of sperm cell motility. In a ... Society Interface, a team led by Michael Berns, an ... of biomedical engineering at the Beckman Laser Institute ...
... sequencing technology that can in one fell swoop decode 50 ... a research team led by University of Delaware scientists is ... switched on or off in rice--a crop vital to the ... which is supported by a $5.3-million grant from the National ...
Cached Biology News:Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 3Primate sperm competition: speed matters 2UD leads $5.3-million research project on rice epigenetics 2UD leads $5.3-million research project on rice epigenetics 3UD leads $5.3-million research project on rice epigenetics 4
iEMS Thermal Microplate Holder...
...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: